EANS-News: Balda AG
Balda shareholders approve dividend payment of EUR 2.00
per share
07.11.2012 – 20:11
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Annual & Special Corporate Meetings Subtitle: - Ted Gerlach elected as new member of the supervisory board - Plastic specialist is in advanced negotiations regarding an acquisition in the Medical division Bielefeld (euro adhoc) - Bielefeld, 7th November 2012 - This Wednesday the annual general meeting of Balda AG, Bad Oeynhausen, approved a dividend payment of EUR 2.00 per share for the short financial year 2012 (1st January to 30th June 2012). As such a total of around EUR 117.8 million will be distributed. The shareholders have therefore once again participated in the proceeds arising from the sale of the majority of the shares in the touchscreen manufacturer TPK Holding during the short financial year. With a presence of 60.1% of the total share capital, the shareholders approved the proposed dividend with a substantial majority. Additionally, the annual general meeting elected Mr Ted Gerlach as a new supervisory board member and successor to Mr Chun-Chen Chen in this role. Mr Gerlach is the Managing Director of BluePoint Controls Inc. with its head office in Milpitas, California, USA. He will bring with him his comprehensive knowledge of the North American market, which is of growing significance to the further development of the Balda Group. The annual general meeting also confirmed the posts of the supervisory board members Dr. Michael Naschke and Mr Yu-Sheng Kai. The board elected Dr. Naschke as supervisory board chairman and Mr Gerlach as his deputy during its constituent session. Chief Executive Officer Dominik Müser reported to the annual general meeting on the progress of the Balda Group's reorientation during the year 2012, principally encompassing a Buy and Build strategy for the Balda Medical segment. The unaltered objective remains to increase the Group's revenues in the next three years to EUR 150 to 200 million, and in doing so to increase the Medical segment revenues to a figure considerably in excess of EUR 100 million. At the present time Balda is in advanced negotiations regarding the acquisition of companies in North America and Western Europe. Dominik Müser, Chief Executive Officer of Balda AG: "We are very confident about the future of Balda. At the beginning of this year we found ourselves faced with many pressing tasks, the greatest part of which we have already taking care of. This includes the implementation of a growth strategy for Balda Medical, the restructuring of the Electronic Products segment and the sale of the majority of the TPK shares. Balda now has every chance of developing into a growing, profitable midcap, one that is valued on the stock market." Note to the editors: The statements made by Chief Executive Officer of Balda AG Dominik Müser at the annual general meeting can be found on the Balda AG website (www.balda.de). Further inquiry note: Frank Elsner Frank Elsner Kommunikation für Unternehmen GmbH Tel.: +49 - 54 04 - 91 92 0 Fax: +49 - 54 04 - 91 92 29 Mail:{office@elsner-kommunikation.de}[HYPERLINK: mailto:office@elsner-kommunikation.de] end of announcement euro adhoc -------------------------------------------------------------------------------- company: Balda AG Bergkirchener Str. 228 D-32549 Bad Oeynhausen phone: +49 (0) 5734 9 22-0 FAX: +49 (0) 5734 922-2747 mail: info@balda.de WWW: http://www.balda.de sector: Semiconductors & active components ISIN: DE0005215107 indexes: CDAX, Prime All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English